Oncurious

. @Oxurion publishes results from Phase 1 trial of THR-687 for #DME treatment; is now recruiting patients for Phase 2 clinical study buff.ly/3AMjs9c

Published papers by @Oxurion in the Journal of Pharmacokinetics and Pharmacodynamics describe desirable #clinicalstudy profiles of THR-149 and THR-687 for #retinalvascular disorders: oxurion.com/content/oxurio… #lifesciences #biopharma #publishing #opthamology

Oxurion NV - Publication of Positive Phase 1 Clinical Data evaluating THR-687 for Treatment of DME in Ophthalmology Science, the American Academy of Ophthalmology Journal globenewswire.com/news-release/2…

As we close out #BrainTumorAwarenessMonth, we hope you will join us & #GiveHopeAName by making a donation to @PBTF in honor of every child who has battled a brain tumor. Donate today: buff.ly/2ToF7UG #CareCureThrive #BrainCancerAwareness #GoGray #BrainTumorAwareness

@VIBLifeSciences @CarmelietLab @vib_ccb @KU_Leuven @americanacad Congratulations Prof. Peter Carmeliet!

Prof. Peter Carmeliet of VIB-KU Leuven Center for Cancer Biology has been elected as an International Honorary Member of the prestigious American Academy of Arts & Sciences (AAAS). Congratulations! vib.be/news/internati…

Beursblik: bemoedigende resultaten bij Oncurious 💪shar.es/aoQQj1

Very excited and proud to present encouraging data from a Phase 1 Phase 1 Dose Escalation Study of #TB403 in Paediatric Subjects with Relapsed or Refractory Medulloblastoma bit.ly/3uHNRlZ #AACR21 #cancerresearch @Oncurious @NMTRC @VIBLifeSciences @CarmelietLab

Oncurious NV Reports Encouraging Data from Phase 1 Dose Escalation Study of TB-403 in Paediatric Subjects with Relapsed or Refractory Medulloblastoma Presented at the American Association for Cancer Research 2021 Annual Meeting globenewswire.com/news-release/2…

Excited to attend and present preclinical and clinical data at the AACR 2021 Annual Meeting! thttps://bit.ly/2PGc2md #ccr8 #immunotherapy #tb403 #medulloblastoma

Journal of ImmunoTherapy for Cancer published research findings by @Oncurious @VIBLifeSciences highlighting efficacy and safety of targeting CCR8 for depletion of tumor-promoting ti-Tregs in combo with anti-PD-1 therapy ap.lc/k3RWw #immunotherapy #cancer #CCR8 #leuven

We've got news from our I-O portfolio! @Oncurious @VIBLifeSciences Announcing First Preclinical Proof of Concept in Proprietary CCR8 Treg Program. Follow the link to our updated website: bit.ly/31OLHoX

Moreover, bij @Oncurious zijn we #ontrack om rond mid 2020 een eerste preklinische PoC voor te stellen We werken aan immuno-oncotherapieën van de volgende generatie voor een breed spectrum van kankertypes. @Oxurion is 85% eigenaar, @VIBLifeSciences 15% #partnersinscience

Congrats to the @Oxurion and @Bicycle_tx team ! 👏

@ONCURIOUS NV Receives $1 M Grant from VLAIO to Progress Pipeline of Next Generation Cancer Immunotherapies bit.ly/2XFrRZ4 #nextlevel

@Oxurion: ook het @Oncurious team blijft niet bij de pakken zitten. Recrutering van 4de (laatste) cohort van patientjes in onze Ph 1/2 studie met antiPlGF voor behandeling van medulloblastoma. Over onze I/O projecten met @VIBLifeSciences hebben we het later nog wel ;-) #staytuned

Today is #WorldCancerDay 🍀. At the CCB we focus every day on #Cancer research, raise #Awareness about it and make it a global priority to #improve early #diagnosis & #discover effective #treatments for all patients.

Our featured story this week! Role of Glutamine Synthetase in Angiogenesis beyond Glutamine Synthesis @LeuvenU @harvardmed @nature @CarmelietLab ow.ly/Ys0z30lMbCc

Congratulations @ThromboGenics ! twitter.com/ThromboGenics/…

Congratulations to Prof Peter Carmeliet @vib_ccb @VIBLifeSciences ! Well deserved! twitter.com/VIBLifeScience…

Hij vertrok vanuit #Leuven om elke dag 76 kilometer te lopen. Aangekomen! Van harte gefeliciteerd @SwinnenJohan ! goo.gl/7FLMZ1